Navigation Links
Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
Date:4/21/2009

>

Of 18 evaluable patients who received the every-four-week FOLPI regimen, 67 percent achieved disease control (partial response and stable disease). Of 55 evaluable patients who received the every-two-week FOLPI regimen, 75 percent achieved disease control.

About Picoplatin

Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that it has an improved safety profile relative to existing platinum-based cancer therapies. More than 1,100 patients have received picoplatin. Results obtained to date suggest manageable hematologic adverse events with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs. Picoplatin has demonstrated anti-tumor activity in a variety of solid tumors. It is being studied in multiple cancer indications, treatment combinations and by two routes of administration.

In addition to the Phase 2 clinical trial in CRC, Poniard is currently evaluating the efficacy and safety of picoplatin in small cell lung cancer in a pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial, which is being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. The Company reached its enrollment target in this international, multi-center, randomized, controlled trial in March 2009. Poniard is also evaluating picoplatin in a Phase 2 clinical trial in patients with castration-resistant (or hormone-refractory) prostate cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information p
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
2. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
3. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
4. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
5. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
6. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
7. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
8. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
9. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
10. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
11. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Denville, NJ (PRWEB) January 22, 2015 ... shearing technologies such as the Bioruptor® and complete ... semi-automation system for chromatin immunoprecipitation, alleviating the need ... reagents and controls needed for ChIP of histones ...
(Date:1/22/2015)... 2015   Cypher Genomics, Inc., the leading ... SQNM ), the leading molecular diagnostics company, ... noninvasive prenatal tests (NIPT). Through this agreement, Sequenom ... to advance analysis of clinically-relevant fetal sub-chromosomal variants ...
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision ... tools to enable the broad use of genomic, imaging and ... the appointment of Michelle Munson , CEO of Aspera, ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/25/2014)... The report “Service Quality Management and ... Provider Type - Global Advancements, Worldwide Forecasts & Analysis ... analysis and forecasting of revenues. , Browse 152 ... and in-depth TOC on “Service Quality Management (SQM) and ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4GenoSpace Expands Board with Appointment of Michelle Munson 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4
... 2011 Halozyme Therapeutics, Inc. (NASDAQ: ... products targeting the extracellular matrix , today announced that ... in New York. The presentation is scheduled for Wednesday, September ... to the live webcast or a replay of the presentation, ...
... carbon material, which combines both graphene and SWNTs, ... have been discovered by researchers from Aalto University ... graphene materials have attracted enormous interest from a ... with the idea to create a novel hybrid ...
... 21, 2011 Generex Biotechnology Corporation,s (OTCBB: GNBT) ( ... ), today announced that its lead drug candidate AE37, ... for the treatment of breast cancer, is featured in ... in a story titled "A New Ally Against Cancer" ...
Cached Biology Technology:Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28 2New hybrid carbon material discovered 2Antigen Express' AE37 Cancer Vaccine Featured in Scientific American 2Antigen Express' AE37 Cancer Vaccine Featured in Scientific American 3Antigen Express' AE37 Cancer Vaccine Featured in Scientific American 4
(Date:1/22/2015)... ROBERTS, Washington , January 20, 2015 ... and tech stocks, releases video from the CES 2015 (Consumer ... consultant Apollo Robbins . Apollo shows how ... biometric smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
(Date:1/22/2015)... 2015   EyeLock, Inc. , a market leader of iris-based ... Gerber to the new role of Senior Vice President ... development of mobile platforms and wearable solutions for EyeLock,s technologies. ... in the semiconductor industry to his role at EyeLock, with ...
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ) has ... Watermarking and Fingerprinting Markets" report to their ... This insight provides an overview of ... Watermarking aims to control and monitor piracy by ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2The Global Watermarking and Fingerprinting Markets 2
... have invented a superthin "nanoglue" that could be used ... semiconductor wafers) would break before the glue peels off," ... his fellow researchers have filed a provisional patent. ... Pan,s nanoglue, which conducts heat and can be printed, ...
... the complexities of biological networks, such as the way in ... by researchers in China. The team,s algorithm could allow biologists ... work and what goes awry with such networks in various ... networks everywhere in technology, in nature, in our bodies. They ...
... Washington, D.C. -- Plant science is key to addressing the ... Carnegie,s David Ehrhardt and Wolf Frommer. In a Perspective published ... that the development of new technology is key to transforming ... Plants serve as the conduit of energy into the biosphere, ...
Cached Biology News:Unraveling biological networks 2The future of plant science - a technology perspective 2
... analysis in a modern flow cytometer, a ... are differentially labeled with fluorescent probes. However, ... used for cell labeling are broader than ... flow cytometers filters. Thus, the fluorescence signal ...
This free-standing laminar flow hood provides a vertical flow of HEPA-filtered air to create a clean processing area. It includes a fluorescent light and motorized sliding shield. Options include wor...
... ,Product Information , ... high quality, general purpose shaker with economical analog ... models in the line, the Orbit LS features ... Electronic controls are utilized for setting speed and ...
This modular laminar flow hood forces air through a 99.99% efficient HEPA filter to create a clean processing area. Configurations are available with vertical or horizontal flow; options include a wo...
Biology Products: